https://www.itmedia.co.jp/news/articles/2005/19/news118.html
シェアしました。
2020年05月19日 18時11分 公開
[芹澤隆徳，ITmedia]
近視の多くは、眼軸長が伸び、眼球の中で焦点が網膜より手前になることで引き起こされる。眼軸長は年齢とともに伸びるか成長が止まるが、それを「初めて逆に動かした」のが今回の技術だ。
クボタビジョンは、人種の異なる21〜32歳の男女12人（近視患者）にアクティブスティミュレーションの試作機を使用させ、「人工的な光により、対象眼と比較して眼軸長の短縮を確認した。世界でも前例がない」としている。詳細なデータは論文として発表する。
ただし、一回の治療に数時間かかるため、試作機のような卓上型デバイスでは患者の負担が大きい。このためアクティブスティミュレーションの技術をメガネやコンタクトレンズに組み込み、日常生活の中で無理なく矯正できる環境を整える考えだ。まず「クボタメガネ」と呼ぶスマートメガネを開発し、年内に実証実験の終了と試作機の完成を目指す。スマートコンタクトレンズの開発も検討している。
窪田製薬ホールディングスの窪田良博士（代表執行役会長、社長兼最高経営責任者）は、「近視患者を対象とした検証で予想以上に良好なデータが得られた」と胸を張る。「近視を撲滅することにより、生活の質を高めることはもちろん、近視によって引き起こされる失明に至る合併症を減らせると期待している」。
Copyright © ITmedia, Inc. All Rights Reserved.
shared.
May 19, 2020 18:11 Published
Kubota Pharmaceutical Holdings Co., Ltd. (Chiyoda-ku, Tokyo) on May
18th, its subsidiary Kubota Vision (Washington, USA) verified the effect
of active stimulation that stimulates the eyes with a special light, To
the retina) has been confirmed. Utilizing this technology, we will develop eyeglass-type devices that can be used for the prevention and treatment of myopia.
Most myopia is caused by an increase in the axial length of the eye, and the focus in the eyeball is closer to the retina. The axial length grows or stops growing with age, but this is the technology that "moved it backwards for the first time."
KUBOTA VISION made 12 men and women aged 21 to 32 (myopia patients) of different races use the prototype of active stimulation and said, "The artificial light shortens the axial length compared to the target eye. It is unprecedented in the world." Detailed data will be published as a paper.
However, since a single treatment takes several hours, a table-top device such as a prototype device imposes a heavy burden on the patient. For this reason, the idea is to incorporate the technology of active stimulation into glasses and contact lenses to create an environment that can be easily corrected in daily life. First of all, we will develop smart glasses called "Kubota glasses" and aim to finish the trial and complete the prototype within the year. We are also considering the development of smart contact lenses.
Dr. Ryo Kubota (Representative Executive Chairman, President and Chief Executive Officer) of Kubota Pharmaceutical Holdings Co., Ltd. exclaims, "We were able to obtain better-than-expected data in the verification of myopia patients." "By eliminating myopia, we hope to improve the quality of life as well as reduce the complications leading to blindness caused by myopia."
Copyright © ITmedia, Inc. All Rights Reserved.
To develop eyeglasses that cure myopia. Special light stimulates the eyes, and Kubota Vision confirms the effect with a prototype. To develop eyeglasses that cure myopia.Stimulate your eyes with a special light and confirm the effect of Kubota Vision on a prototype.
https://www.itmedia.co.jp/news/articles/2005/19/news118.html Weshared.
May 19, 2020 18:11 Published
Most myopia is caused by an increase in the axial length of the eye, and the focus in the eyeball is closer to the retina. The axial length grows or stops growing with age, but this is the technology that "moved it backwards for the first time."
KUBOTA VISION made 12 men and women aged 21 to 32 (myopia patients) of different races use the prototype of active stimulation and said, "The artificial light shortens the axial length compared to the target eye. It is unprecedented in the world." Detailed data will be published as a paper.
However, since a single treatment takes several hours, a table-top device such as a prototype device imposes a heavy burden on the patient. For this reason, the idea is to incorporate the technology of active stimulation into glasses and contact lenses to create an environment that can be easily corrected in daily life. First of all, we will develop smart glasses called "Kubota glasses" and aim to finish the trial and complete the prototype within the year. We are also considering the development of smart contact lenses.
Dr. Ryo Kubota (Representative Executive Chairman, President and Chief Executive Officer) of Kubota Pharmaceutical Holdings Co., Ltd. exclaims, "We were able to obtain better-than-expected data in the verification of myopia patients." "By eliminating myopia, we hope to improve the quality of life as well as reduce the complications leading to blindness caused by myopia."
Copyright © ITmedia, Inc. All Rights Reserved.
0 コメント:
コメントを投稿